Heparan sulfate subdomains that are degraded by Sulf accumulate in cerebral amyloid ß plaques of Alzheimer's disease: evidence from mouse models and patients.
暂无分享,去创建一个
Tony Wyss-Coray | T. Wyss-Coray | M. Britschgi | M. Michikawa | T. V. van Kuppevelt | H. Akatsu | Toin H van Kuppevelt | Markus Britschgi | Kazuchika Nishitsuji | Hiroyasu Akatsu | K. Kimata | Kenji Uchimura | Koji Kimata | Makoto Michikawa | Tomomi Hosono-Fukao | Shiori Ohtake-Niimi | Hitomi Hoshino | Md Motarab Hossain | M. Hossain | K. Uchimura | Kazuchika Nishitsuji | H. Hoshino | Tomomi Hosono-Fukao | Shiori Ohtake-Niimi | Markus Britschgi
[1] S. Younkin,et al. Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.
[2] V. Uversky,et al. Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro. , 2002, Biochemistry.
[3] V. Mathura,et al. Impaired Orthotopic Glioma Growth and Vascularization in Transgenic Mouse Models of Alzheimer's Disease , 2010, The Journal of Neuroscience.
[4] D. Walsh,et al. Exogenous Induction of Cerebral ß-Amyloidogenesis Is Governed by Agent and Host , 2006, Science.
[5] D. Selkoe,et al. Heparin-binding properties of the amyloidogenic peptides Abeta and amylin. Dependence on aggregation state and inhibition by Congo red. , 1997, The Journal of biological chemistry.
[6] Kang Hu,et al. High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.
[7] C. Parish. The role of heparan sulphate in inflammation , 2006, Nature Reviews Immunology.
[8] Z. Werb,et al. Cloning and Characterization of Two Extracellular Heparin-degrading Endosulfatases in Mice and Humans* , 2002, The Journal of Biological Chemistry.
[9] F. Chiti,et al. Kinetic Analysis of Amyloid Formation in the Presence of Heparan Sulfate , 2009, The Journal of Biological Chemistry.
[10] Anders Wallin,et al. Increased intrathecal levels of the angiogenic factors VEGF and TGF-β in Alzheimer’s disease and vascular dementia , 2002, Neurobiology of Aging.
[11] M. Verbeek,et al. Limited expression of heparan sulphate proteoglycans associated with Aβ deposits in the APPswe/PS1dE9 mouse model for Alzheimer's disease , 2010, Neuropathology and applied neurobiology.
[12] P. Wesseling,et al. Heparan sulfate proteoglycan expression in cerebrovascular amyloid β deposits in Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis (Dutch) brains , 2001, Acta Neuropathologica.
[13] R. Kalaria,et al. Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain. , 1994, American Journal of Pathology.
[14] I. Vlodavsky,et al. In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[15] A. Minton,et al. Quantitative Characterization of Heparin Binding to Tau Protein , 2009, The Journal of Biological Chemistry.
[16] M. Rafii,et al. Agrin in Alzheimer's Disease: Altered Solubility and Abnormal Distribution within Microvasculature and Brain Parenchyma , 1999 .
[17] T. Wight,et al. The Sulfate Moieties of Glycosaminoglycans Are Critical for the Enhancement of β‐Amyloid Protein Fibril Formation , 1999, Journal of neurochemistry.
[18] J. Ávila,et al. Glycosaminoglycans and β-amyloid, prion and tau peptides in neurodegenerative diseases , 2002, Peptides.
[19] P. Hof,et al. The nature and effects of cortical microvascular pathology in aging and Alzheimer's disease , 2004, Neurological research.
[20] P. Fraser,et al. An important role of heparan sulfate proteoglycan (perlecan) in a model system for the deposition and persistence of fibrillar aβ-amyloid in rat brain , 1994, Neuron.
[21] Y. T. Wang,et al. Microglial VEGF Receptor Response Is an Integral Chemotactic Component in Alzheimer's Disease Pathology , 2009, The Journal of Neuroscience.
[22] Berislav V. Zlokovic,et al. Neurovascular mechanisms of Alzheimer's neurodegeneration , 2005, Trends in Neurosciences.
[23] P. Wesseling,et al. Agrin is a major heparan sulfate proteoglycan accumulating in Alzheimer's disease brain. , 1999, The American journal of pathology.
[24] K. Brunden,et al. Proteoglycan-mediated inhibition of A beta proteolysis. A potential cause of senile plaque accumulation. , 1995, The Journal of biological chemistry.
[25] R. Dom,et al. Heparan sulfate expression patterns in the amyloid deposits of patients with Alzheimer's and Lewy body type dementia. , 1993, Dementia.
[26] Jeffrey D. Esko,et al. Heparan sulphate proteoglycans fine-tune mammalian physiology , 2007, Nature.
[27] L. Eriksson,et al. Structure of heparan sulphate from human brain, with special regard to Alzheimer's disease. , 1995, The Biochemical journal.
[28] R. Iozzo. Matrix proteoglycans: from molecular design to cellular function. , 1998, Annual review of biochemistry.
[29] J. Ávila,et al. Polymerization of tau into filaments in the presence of heparin: the minimal sequence required for tau-tau interaction. , 1996, Journal of neurochemistry.
[30] S. Selleck,et al. Order out of chaos: assembly of ligand binding sites in heparan sulfate. , 2002, Annual review of biochemistry.
[31] J. Johansson,et al. Heparan sulfate/heparin promotes transthyretin fibrillization through selective binding to a basic motif in the protein , 2011, Proceedings of the National Academy of Sciences.
[32] M. Mallory,et al. Early formation of mature amyloid‐β protein deposits in a mutant APP transgenic model depends on levels of Aβ1–42 , 2001, Journal of neuroscience research.
[33] H. Nakato,et al. Heparan sulfate fine structure and specificity of proteoglycan functions. , 2002, Biochimica et biophysica acta.
[34] D. Spillmann,et al. Heparin/Heparan Sulfate Biosynthesis , 2008, Journal of Biological Chemistry.
[35] J. LaManna,et al. Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia. , 1998, Brain research. Molecular brain research.
[36] J. Trojanowski,et al. Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. , 2006, Annual review of pathology.
[37] J. van den Born,et al. Novel Heparan Sulfate Structures Revealed by Monoclonal Antibodies* , 2005, Journal of Biological Chemistry.
[38] Ilona B. Bruinsma,et al. Sulfation of heparan sulfate associated with amyloid-β plaques in patients with Alzheimer’s disease , 2010, Acta Neuropathologica.
[39] Z. Werb,et al. Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer. , 2005, Neoplasia.
[40] J. Esko,et al. Molecular diversity of heparan sulfate. , 2001, The Journal of clinical investigation.
[41] Ilona B. Bruinsma,et al. Aggregation and cytotoxic properties towards cultured cerebrovascular cells of Dutch-mutated Aβ40 (DAβ1-40) are modulated by sulfate moieties of heparin , 2010, Neuroscience Research.
[42] C. Bertozzi,et al. Compositional profiling of heparin/heparan sulfate using mass spectrometry: assay for specificity of a novel extracellular human endosulfatase. , 2005, Glycobiology.
[43] C. Chirita,et al. Pathways of tau fibrillization. , 2005, Biochimica et biophysica acta.
[44] J. Gallagher. Heparan sulfate: growth control with a restricted sequence menu. , 2001, The Journal of clinical investigation.
[45] P. Fraser,et al. Interactions of Alzheimer amyloid-beta peptides with glycosaminoglycans effects on fibril nucleation and growth. , 1999, European journal of biochemistry.
[46] J. Ávila,et al. Polymerization of τ into Filaments in the Presence of Heparin: The Minimal Sequence Required for τ ‐ τ Interaction , 1996 .
[47] D. Nochlin,et al. The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease. , 1988, The American journal of pathology.
[48] C. Masters,et al. The Amyloid Precursor Protein (APP) of Alzheimer Disease and Its Paralog, APLP2, Modulate the Cu/Zn-Nitric Oxide-catalyzed Degradation of Glypican-1 Heparan Sulfate in Vivo* , 2005, Journal of Biological Chemistry.
[49] B. Hyman,et al. Heparan Sulfate Accumulation with Aβ Deposits in Alzheimer's Disease and Tg2576 Mice is Contributed by Glial Cells , 2008, Brain pathology.
[50] T. V. van Kuppevelt,et al. Direct detection of HSulf-1 and HSulf-2 activities on extracellular heparan sulfate and their inhibition by PI-88. , 2010, Glycobiology.
[51] M. Moskowitz,et al. Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy. , 2001, The American journal of pathology.
[52] M. Götte,et al. Functions of cell surface heparan sulfate proteoglycans. , 1999, Annual review of biochemistry.
[53] R. Crowther,et al. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans , 1996, Nature.
[54] R. Kisilevsky,et al. The Heparin/Heparan Sulfate-binding Site on Apo-serum Amyloid A , 1999, The Journal of Biological Chemistry.
[55] P. Fraser,et al. Effect of amino-acid substitutions on Alzheimer's amyloid-beta peptide-glycosaminoglycan interactions. , 2000, European journal of biochemistry.
[56] J. Samitier,et al. Modulation of Aβ42 fìbrillogenesis by glycosaminoglycan structure , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[57] E. Versteeg,et al. Large, Tissue-regulated Domain Diversity of Heparan Sulfates Demonstrated by Phage Display Antibodies* , 2002, The Journal of Biological Chemistry.
[58] P. Wesseling,et al. Heparan sulphate proteoglycans in Alzheimer's disease and amyloid‐related disorders , 2003, The Lancet Neurology.
[59] P. Cras,et al. Basic fibroblast growth factor binding is a marker for extracellular neurofibrillary tangles in Alzheimer disease. , 1991, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[60] Thomas Krucker,et al. Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease , 2008, Proceedings of the National Academy of Sciences.
[61] J. Veerkamp,et al. Heparan Sulfate Heterogeneity in Skeletal Muscle Basal Lamina: Demonstration by Phage Display-Derived Antibodies , 2000, The Journal of Neuroscience.
[62] M. Michikawa,et al. RB4CD12 epitope expression and heparan sulfate disaccharide composition in brain vasculature , 2011, Journal of neuroscience research.
[63] Z. Werb,et al. HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1 , 2006, BMC Biochemistry.
[64] S. Supattapone. Prion protein conversion in vitro , 2004, Journal of Molecular Medicine.